News | 13 March 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The programme will take place on the 2nd Sunday of every month
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Havix was incorporated under the laws of the State of Delaware on February 17, 2015
The European regulator will conduct a re-inspection of the facility to verify the compliance
The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Encourages working women to practice self-care
Overall investment in the US facility is estimated around US$50 million
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Amaran Biotech boasts Taiwan’s first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals
VITADEETM Green is a 100% plant-based Vitamin D3 suitable for food & nutraceuticals
There are 38.4 million people with diabetes in the United States
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
ANVIMO will be available in dosages of 240 mg and 480 mg
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Subscribe To Our Newsletter & Stay Updated
